Your browser doesn't support javascript.
loading
Favorable treatment response of bevacizumab-combined chemotherapy for advanced or recurrent invasive mucinous adenocarcinoma of the lung: A retrospective observational study.
Fujimoto, Kazushi; Sekine, Akimasa; Hagiwara, Eri; Asaoka, Masato; Ikeda, Satoshi; Baba, Tomohisa; Komatsu, Shigeru; Ogura, Takashi.
Afiliación
  • Fujimoto K; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan. Electronic address: fujimoto.8x50n@kanagawa-pho.jp.
  • Sekine A; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan.
  • Hagiwara E; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan.
  • Asaoka M; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan.
  • Ikeda S; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan.
  • Baba T; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan.
  • Komatsu S; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan.
  • Ogura T; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0051, Japan.
Respir Investig ; 62(3): 360-364, 2024 May.
Article en En | MEDLINE | ID: mdl-38428089
ABSTRACT
Invasive mucinous adenocarcinoma (IMA) of the lung is a rare variant of adenocarcinoma characterized by abundant intracytoplasmic mucin within the tumor. Although IMA has poor sensitivity to conventional chemotherapy regimens used for non-small cell lung cancer, we observed a better response to the bevacizumab (BEV) regimen. In this retrospective study, we aimed to investigate the response to BEV-combined regimens in patients with IMA. Among 16 consecutive patients diagnosed with IMA between January 2016 and December 2020 at our institution and treated with systemic chemotherapy, seven patients were treated with BEV-combined regimens. The overall response rate to BEV-combined regimens was 85.7%, with six patients showing a partial response. The median progression-free survival was 6.1 months. One patient experienced respiratory failure, which was improved after administration of BEV-combined regimen. BEV-combined systemic therapy may have a favorable effect on advanced or recurrent IMA of the lung.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Carcinoma de Pulmón de Células no Pequeñas / Adenocarcinoma Mucinoso / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Respir Investig Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Carcinoma de Pulmón de Células no Pequeñas / Adenocarcinoma Mucinoso / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Respir Investig Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos